EDCTs: How biostatistics can benefit clinical trials

Our presentation at the COG CRO Summit will showcase how biostatistical expertise is adapting to the ever-changing landscape of clinical trials. Discover: • Current trends in biostatistics for clinical trials • Best practices for integrating statistical methodologies • Future directions in data-driven clinical development Join us in Raleigh on December 3-4, 2024, and empower your decision-making with valuable insights! #ClinicalTrialInnovation #Biostatistics #COGCRO2024 #SDCclinical #SDCInsights #SDCCapture

Do you want to improve your understanding of complex sequential analysis trials? Join us tomorrow for a free webinar where you can gain valuable insights and skills in study design and evaluation. Don't miss this opportunity to expand your knowledge and expertise in Sequential Analysis, Clinical Trials, and Biostatistics. Register now to secure your spot: https://bit.ly/4bfDVVX #SequentialAnalysis #ClinicalTrials #Biostatistics

Behind every successful clinical or real-world evidence study is robust biostatistics. At Epistat, we support you from study design to insightful analysis and impactful reporting, ensuring your data makes a meaningful difference. Let’s take your clinical research to the next level! 📊✨ Contact us 📩 at info@epistat.se for more information, or visit our website 🌐 to learn more: www.epistat.se #ClinicalTrials #RealWorldEvidence #Biostatistics #MedicalResearch

Biostatistics for Non-biostatisticians: Relative Risk Relative risk is a valuable statistical measure used in clinical trials to compare the likelihood of a certain event occurring in one group versus another. Specifically, Relative risk is most useful when the outcomes are binary, meaning they have only two possible states, such as success or failure: Presence or absence of disease (example table below), etc. This measure tells us how much more likely (or less likely) an event is to occur in the treatment group compared to the control group. Why not calculate the difference between the two risks? The proportional nature of relative risk can often be more intuitive and meaningful, especially in communicating the strength of an association or the effectiveness of an intervention. For example, a relative risk of 2.0 indicates that the event is twice as likely to occur in the treatment group, which can be more striking than stating the risk difference of 25%. If you would like to learn more about relative risk and other statistical measures, please stick around, I have a lot of material lined up that covers a wide variety of statistical terms, definitions, and analysis methods on the horizon. Happy Tuesday.

I would highly recommend their intensive and invaluable course to anyone looking to advance their expertise in biostatistics. #Biostatistics #ProfessionalDevelopment #Recommendation

A good experience that made me a professional in biostatistics using R.

A research team, led by Ting Ye, assistant professor of UW Department of Biostatistics at the UW School of Public Health, has been awarded $1 million by the Patient-Centered Outcomes Research Institute (PCORI) to innovate clinical platform trials that aims to improve patient care. “What makes this work particularly exciting is not only the innovation and statistical rigor we bring to platform trials but also our collaboration with a diverse stakeholder panel. Their perspectives and insights will be invaluable to our investigative team and the broader impact of this research." Read the announcement here: https://lnkd.in/gxpKk4b3 #PublicHealth #Biostatistics #ClinicalResearch

The notion of ‘precision medicine‘ or tailoring diagnostics and therapeutics based on individual patient characteristics isn’t new. What is new is the growing availability of patient-specific standardized data ranging from core EHR data to patient-generated health data. Elimu Informatics’ vision for Precision Medicine is to leverage this full spectrum of patient-specific data for advanced clinical decision making. In our new blog, we focus on genetic sequencing data and emerging FHIR-based strategies for exposing a person’s entire genome for clinical decision support (CDS). Read our newest blog here: https://lnkd.in/eXdmYwxV #PrecisionMedicine #HealthTech #FHIR #HealthcareInnovation #DigitalHealth #HealthcareTechnology #MedicalInnovation #HealthData #Interoperability #HealthIT #DataScience #Bioinformatics #HealthcareAnalytics #PersonalizedMedicine #HealthcareRevolution #HealthcareTech #EHR #MedicalResearch #ClinicalInformatics

What is the relevance of biostatistics in the Clinical Trials path? Let's see the impact biostatisticians can have from Pre-Clinical.